MAP6 and CRMP2 may be simultaneously phosphorylated by GSK3β at shared or interacting sites, creating a coordinated phosphorylation code that regulates microtubule dynamics in response to guidance cues
Prediction: Simultaneous disruption of MAP6 and CRMP2 phosphorylation sites would produce more severe axon guidance defects than single knockouts, and neuronal activity-dependent phosphorylation events would show correlated changes in both proteins
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["MAPT/Tau Occupancy Dynamic Microtubule Binding"]
B["MAP6 Occupancy Cold-Stable Domain Support"]
C["Shared Microtubule Lattice Domain Allocation Competition"]
D["GSK3B/CRMP2 Cue Integration Plasticity Signaling"]
E["Axonal Remodeling Balance Stable vs Labile Segments"]
F["Transport and Branching Adaptive Circuit Plasticity"]
G["Tau-MAP6 Imbalance Rigid or Unstable Cytoskeleton"]
A --> C
B --> C
C --> D
D --> E
E --> F
G -.->|"disrupts"| C
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations5 with PMID5 mediumValidation: 0%6 supporting / 0 opposing
✓For(6)
5
No opposing evidence
(0)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
2
2
MECH 2CLIN 2GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Druggability of CRMP2 for Neurodegenerative Diseas…
MAP6 and CRMP2 may be simultaneously phosphorylate…
Supporting
MECH
-
-
-
-
-
-
Legacy Card View — expandable citation cards
✓ Supporting Evidence
6
MAP6 and CRMP2 may be simultaneously phosphorylated by GSK3β at shared or interacting sites, creating a coordi…▼
MAP6 and CRMP2 may be simultaneously phosphorylated by GSK3β at shared or interacting sites, creating a coordinated phosphorylation code that regulates microtubule dynamics in response to guidance cues
Druggability of CRMP2 for Neurodegenerative Diseases.MEDIUM
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Theoretical Evaluation: MAP6 and CRMPs in Neuronal Function and Neurodegeneration
1. Key Scientific Contributions
1.1 Unification of MAP6's Pleiotropic Functions Under a Single Conceptual Framework
This review synthesizes two decades of work demonstrating that MAP6 (STOP) is far more than a microtubule stabilizer. The authors establish MAP6 as a signaling scaffold that coordinates microtubule dynamics, actin cytoskeleton remodeling, and receptor trafficking. This reframing is significant because it positions MAP6 as a potential integrator of cytoskeletal responses to neuronal ac
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: MAP6 and CRMPs Review Article
1. Key Methodological Weaknesses
1.1 Literature Synthesis Lacks Systematic Rigor
This is a narrative review, not a systematic review. The authors present their interpretation of "extensive data obtained over 20 years" without transparent inclusion/exclusion criteria for studies. This introduces selection bias—the review naturally emphasizes work from the authors' own laboratory (Grenoble Institut Neurosciences) while potentially underrepresenting conflicting findings. A cursory PubMed search reveals that several key authors appe
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Expert Assessment: MAP6 and CRMPs Review Article (PMID: 34025352)
1. Novelty Rating: 6/10
This review provides moderate conceptual novelty within the broader MAP/c cytoskeleton field.
Strengths:
First comprehensive synthesis linking MAP6 to such a diverse array of neuronal functions
The MAP6-CRMPS convergence framework is genuinely informative, as these protein families have been studied largely in parallel
The "beyond stabilization" framing articulates an important shift in thinking about MAPs generally
Limitations:
As a narrative review, novelty is constrained by
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"summary":"This 2021 review from the Grenoble research group synthesizes two decades of research on MAP6 (STOP), repositioning it from a simple microtubule stabilizer to a multifunctional signaling scaffold that coordinates cytoskeletal dynamics, actin remodeling, and receptor trafficking. The authors articulate a convergence framework linking MAP6 to the CRMP family (collapsin response mediator proteins), highlighting shared roles in semaphorin signaling, axon guidance, and GSK3β-mediated phosphorylation. The review extends MAP6 function beyond microtubule binding to encompass synaptic plast
IF primary rodent hippocampal neurons are treated with a selective GSK3β inhibitor (CHIR99021, 10 μM) for 24 hours, THEN phospho-S9-GSK3β inhibition will produce a coordinated decrease in p-CRMP2(S522) and p-MAP6(S236) levels with a correlation coefficient >0.7 across neuronal preparations, within 48 hours post-treatment
pendingconf: 0.65
Expected outcome: Simultaneous reduction of p-MAP6(S236) and p-CRMP2(S522) by >40% in western blot analysis, with correlated temporal dynamics between the two phosphoproteins
Falsified by: GSK3β inhibition affects phosphorylation of only one protein (MAP6 or CRMP2) while leaving the other unchanged; or phosphorylation changes are anti-correlated (r < 0.0); or neither protein's phosphorylation is significantly altered
Method: Primary hippocampal neurons (E18 Sprague-Dawley, DIV 7-10) treated with GSK3β inhibitor, harvested at 0, 6, 12, 24, 48h for phospho-specific western blot using antibodies against p-CRMP2(S522) (Cell Signaling #9394) and p-MAP6(S236) (custom antibody), normalized to total CRMP2 and MAP6
IF CRISPR-Cas9 is used to generate MAP6 S236A;CRMP2 S522A double knock-in mice (simultaneous alanine substitution at both phosphorylation sites), THEN cortical neurons from these mice will display exaggerated growth cone collapse (>60% collapse rate) and microtubule plus-end instability (>30% reduction in EB3 comet velocity) compared to either single mutant line when exposed to Sema3A (100 ng/mL) for 30 minutes
pendingconf: 0.55
Expected outcome: Double mutants show synergistic increase in growth cone collapse percentage and decrease in microtubule polymerization rate relative to single mutants and wild-type controls
Falsified by: Double mutant phenotype is statistically indistinguishable from wild-type (no facilitation); or single mutant phenotypes are equal to or greater than double mutant (no cooperative requirement); or microtubule dynamics are unaffected in all genotypes
Method: CRISPR-Cas9 editing to create double point mutants in C57BL/6J mice; primary cortical neuron cultures from E14.5 embryos; growth cone collapse assay with semaphorin 3A (Peprotech) after 30 min; EB3-GFP live-cell imaging to measure microtubule plus-end dynamics; blinded manual scoring of 100+ growth cones per condition
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
Predicted Protein Structure
🔮
MAP6 — AlphaFold Prediction Q96JE9Click to expand 3D viewer
AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click